Opinion: Limb Girdle Muscular Dystrophy Patients Face a Maddening Reality

Regulatory expedited pathways designed to accelerate patient access to breakthrough treatments are paradoxically being used to prevent drug approvals, according to medical experts. Limb girdle muscular dystrophy (LGMD) patients are particularly affected by this regulatory contradiction, facing delays in accessing potentially life-changing therapies. These accelerated approval mechanisms, intended to benefit patients with serious conditions, are instead creating barriers that prevent innovative treatments from reaching those who need them most. The misuse of regulatory tools highlights a critical gap between the intent of fast-track programs and their actual implementation in clinical practice.